Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | TYMP | P19971 | 3/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | CCR10 | P46092 | 2/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8558881 | 0.93 | KMT2A (0.47) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL6131548 | 0.83 | CA12 (0.44) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL6131613 | 0.81 | LMNA (0.47) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL11348169 | 0.80 | KMT2A (0.62) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL3843843 | 0.80 | KMT2A (0.45) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL5311355 | 0.80 | KMT2A (0.45) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL6131546 | 0.80 | KMT2A (0.45) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL5310582 | 0.80 | KMT2A (0.45) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| Hydrochloric Acid SCHEMBL11455609 | 0.79 | KMT2A (0.60) | KMT2ALMNATHRBCYP2C19CYP3A4 | |
| SCHEMBL8855479 | 0.77 | KMT2A (0.58) | KMT2ALMNATHRBCYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | BRACCO SUISSE SA (CH) | 2004-01-15 | — | — | US | claimed |
| US-20020054853-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO SUISSE SA (CH) | 2002-05-09 | — | — | US | claimed |
| US-5808091-A | DIAGNOSTIC IMAGING AGENT | BRACCO INTERNATIONAL B.V. | 1998-09-15 | — | — | US | claimed |
| US-6958141-B2 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 2005-10-25 | — | — | US | disclosed |
| US-20040191174-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO SUISSE SA (CH) | 2004-09-30 | — | — | US | disclosed |
| US-6699458-B2 | CELL MEMBRANE PERMEABILITIES GREATER THAN THAT OF SUCROSE | BRACCO INTERNATIONAL B.V. (NL) | 2004-03-02 | — | — | US | disclosed |
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | BRACCO SUISSE SA (CH) | 2004-01-15 | — | — | US | disclosed |
| US-20020054853-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO SUISSE SA (CH) | 2002-05-09 | — | — | US | disclosed |
| US-6359120-B1 | REACTING ALKYLENE DIAMINE WITH HALOKETONE TO PROVIDE AN ALKYLENE DIAMINEDIKETONE WHICH IS CONVERTED TO ALKYLENE DIAMINEDIOXIME; OR REACTING ALKYLENE DIAMINE WITH FIRST HALOKETONE AND REACTING WITH SECOND HALOKETONE | BRACCO INTERNATIONAL B.V. (NL) | 2002-03-19 | — | — | US | disclosed |
| US-6184361-B1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 2001-02-06 | — | — | US | disclosed |
| US-5808091-A | DIAGNOSTIC IMAGING AGENT | BRACCO INTERNATIONAL B.V. | 1998-09-15 | — | — | US | disclosed |
| US-5688487-A | Diagnostic imaging methods using rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020054853-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | HIF1A, HIF1AN, SLC2A8 | KMT2A 2657/4885LMNA 4114/4885THRB 618/4885 |
| US-20040191174-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | HIF1A, HIF1AN, SLC2A8 | KMT2A 2657/4885LMNA 4114/4885THRB 618/4885 |
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | HIF1A, HIF1AN, SLC2A8 | KMT2A 2657/4885LMNA 4114/4885THRB 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.